In addition, 97.5% of breast cancers, 79.1% of endometrial cancers, and 97.1% of prostate cancers in the TCGA datasets also expressed GnRHR (Figure 1B), suggesting that GnRHR targeting may be effective in other hormone-related tumors. This evidence concerns the gene GNRHR and prostate carcinoma.